24 completed, 2 not yet recruiting, 2 unknown, 1 recruiting. 9 Phase 2, 8 Phase 3, 4 Not applicable, 4 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Phase 3 | 8 | Completed 7, Unknown 1 |
| Not applicable | 4 | Completed 3, Recruiting 1 |
| Phase 4 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Impetigo: new trials by email Literature Review of Impetigo trials Research Report on Impetigo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis Atopic Dermatitis (AD), Scabies | Not yet recruiting | Istanbul Medeniyet University | 51 | 2026-10-01 | 2026-09-15 | |
| Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center Tonsillitis Acute, Pneumonia - Bacterial | Not yet recruiting | University Hospital, Montpellier | 191 | 2026-09-01 | 2026-07-17 | |
| Perspectives on Antibiotics and Tracking Symptoms in Children Garmin Smartwatch - Urinary Tract Infection, Cellulitis | Not applicable | Recruiting | Murdoch Childrens Research Institute | 300 | 2025-09-16 | 2026-10-07 |
| Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists AI-based medical device for aided diagnosis in Dermatology - Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP) | Completed | AI Labs Group S.L | 15 | 2024-06-01 | 2026-02-24 | |
| Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care Default Duration order Panel - Cellulitis, Abscess | Not applicable | Completed | Nationwide Children's Hospital | 1634 | 2021-11-01 | 2025-04-08 |
| Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo ATx201, ATx201 GEL Vehicle - Impetigo | Phase 2 | Completed | UNION therapeutics | 210 | 2018-02-23 | 2018-07-31 |
| Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji 3 drug dose - IDA, 3 drug dose - IDA with second dose of ivermectin, 2 drug dose - DA - Lymphatic Filariases, Scabies | Not applicable | Completed | Washington University School of Medicine | 4773 | 2017-07-13 | 2020-12-31 |
| Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo Screening, Tele-dermatology - Erysipelas, Impetigo | Not applicable | Completed | Centro Studi Gised | 461 | 2016-10-01 | 2019-05-17 |
| Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Ivermectin, Azithromycin, Permethrin - Scabies, Yaws | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 1291 | 2016-07-01 | 2019-09-17 |
| Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Ozenoxacin, Placebo - Impetigo | Phase 3 | Completed | Ferrer Internacional S.A. | 412 | 2014-06-01 | 2024-08-20 |
| Safety and Efficacy of Mupirocin Gel in Children With Impetigo Mupirocin gel, Mupirocin ointment, Placebo - Impetigo | Phase 3 | Completed | Reig Jofre Group | 467 | 2014-02-01 | 2021-03-12 |
| The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial papaya 1% extract ointment, mupirocin 2% ointment - Impetigo | Phase 1 | Unknown | Philippine Dermatological Society | 128 | 2013-08-01 | 2013-12-19 |
| A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo LTX-109 1 %, LTX-109 2 %, Placebo gel - Non-bullous Impetigo | Phase 2 | Completed | Lytix Biopharma AS | 210 | 2013-02-01 | 2014-04-28 |
| ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) ALTARGO(retapamulin) - Skin Infections, Bacterial | Completed | GlaxoSmithKline | 3612 | 2012-11-01 | 2015-09-23 | |
| Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID - Impetigo | Phase 2 / Phase 3 | Completed | NovaBay Pharmaceuticals, Inc. | 328 | 2012-08-01 | 2014-08-12 |
| Citriodiol® and Impetigo p-menthane-3,8-diol oil - Impetigo | Phase 2 / Phase 3 | Unknown | Royal North Shore Hospital | 30 | 2012-07-01 | 2012-06-20 |
| Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo ozenoxacin placebo, retapamulin 1% ointment, ozenoxacin 1% cream - Impetigo | Phase 3 | Completed | Ferrer Internacional S.A. | 465 | 2012-03-01 | 2016-07-01 |
| A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection LTX-109 - Gram-positive, Skin Infections, Mild Eczema/Dermatoses | Phase 2 | Completed | Lytix Biopharma AS | 24 | 2010-09-01 | 2011-02-16 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Topical Minocycline Foam FXFM244 - Impetigo | Phase 2 | Completed | Vyne Therapeutics Inc. | 32 | 2010-08-01 | 2013-12-10 |
| Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Retapamulin (Altabax) - Impetigo, Folliculitis | Phase 4 | Completed | The University of Texas Health Science Center, Houston | 38 | 2010-04-01 | 2016-02-17 |
Showing 20 of 30. Sign in to see all of them.
Cellulitis (7) · Scabies (4) · Dermatitis, Atopic (3) · Infections (3) · Skin Diseases (3) · Otitis Media (2) · Tinea (2) · Abscess (1) · Acne Conglobata (1) · Acne Vulgaris (1) · Acute Generalized Exanthematous Pustulosis (1) · Alzheimer Disease (1) · Carcinoma, Basal Cell (1) · Carcinoma, Squamous Cell (1)
Bacterial Infections (30) · Bacterial Infections and Mycoses (30) · Gram-Positive Bacterial Infections (30) · Skin Diseases, Bacterial (30) · Skin Diseases, Infectious (30) · Skin and Connective Tissue Diseases (30) · Staphylococcal Skin Infections (30) · Staphylococcal Infections (29) · Streptococcal Infections (29) · Infections (27) · Skin Diseases (27) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Suppuration (8) · Connective Tissue Diseases (7)
Mupirocin (4) · retapamulin (4) · Ointments (2) · ozenoxacin (2) · Azithromycin (1) · Fusidic Acid (1) · Ivermectin (1) · L-arginyl-2,5,7-tris(1,1-dimethylethyl)-L-tryptophyl-N-(2-phenylethyl)-L-argininamide (1) · Linezolid (1) · Mass Screening (1) · NVC-422 (1) · Permethrin (1) · terpin (1)
GlaxoSmithKline (5) · LEO Pharma (3) · Ferrer Internacional S.A. (2) · Lytix Biopharma AS (2) · NovaBay Pharmaceuticals, Inc. (2) · AI Labs Group S.L (1) · Centro Studi Gised (1) · Istanbul Medeniyet University (1) · London School of Hygiene and Tropical Medicine (1) · Menzies School of Health Research (1) · Murdoch Childrens Research Institute (1) · Nationwide Children's Hospital (1) · Philippine Dermatological Society (1) · Reig Jofre Group (1) · Royal North Shore Hospital (1)
United States (7) · South Africa (6) · Australia (3) · Germany (3) · Mexico (3) · Netherlands (3) · Costa Rica (2) · Dominican Republic (2) · India (2) · Italy (2) · Peru (2) · Spain (2) · Argentina (1) · Canada (1) · Chile (1)
Adelaide A Hebert, M.D. (1) · Almena L Free, MD (1) · Andrew Steer, PhD (1) · Antonio Martorell, PhD (1) · Bart Currie, MBBS, DTM&H (1) · Christine Connors, MBBS (1) · Christopher King, MD PhD (1) · Colin J Parker, MBBS (1) · Daisy M Blanco, MD (1) · Daisy M. Blanco, MD (1) · Gary Weil, MD (1) · Janine L. Quijano, MD (1)
PMID 30365584, PMID 19936297, PMID 25396674, PMID 28491950, PMID 29898217, PMID 29985978, PMID 33728462, PMID 34758017, PMID 39665614